[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  PharmaEssentia Corporation PharmaEssentia is hiring across multiple departments, with positive sentiment around patient events and partnerships. New FDA Form XXX posted, indicating potential regulatory scrutiny. ### About PharmaEssentia Corporation PharmaEssentia Corporation is a biopharmaceutical company. ### Insights [#](/topic/$6446tw/insights) - PharmaEssentia Corporation creators is up XXXXX% from the previous week. - PharmaEssentia Corporation engagements is up XXXXX% from the previous week. - PharmaEssentia Corporation mentions is up XXXXX% from the previous week. ### Price: $ [#](/topic/$6446tw/close) ---  [Price 24-Hour Chart Data](/topic/$6446tw/time-series/close.tsv) The price appears stable, likely due to positive Phase X data and anticipation for EHA 2025 presentations, despite the recent FDA Form XXX. **1-Year High**: $XXX on 2025-02-17 **1-Year Low**: $XXXXXX on 2025-04-09 ### AltRank: undefined [#](/topic/$6446tw/alt_rank) ---  [AltRank 24-Hour Chart Data](/topic/$6446tw/time-series/alt_rank.tsv) PharmaEssentia Corporation is currently AltRank #undefined based on combined combined social and market metrics **Daily Average**: XXXXX **1-Year High**: XXXXX on 2025-01-21 **1-Year Low**: XX on 2025-03-13 ### Galaxy Score: XX [#](/topic/$6446tw/galaxy_score) ---  [Galaxy Score 24-Hour Chart Data](/topic/$6446tw/time-series/galaxy_score.tsv) **Current Value**: XX **Daily Average**: XX **1-Year High**: XX on 2025-06-25 **1-Year Low**: XX on 2025-02-08 ### Engagements: XX [#](/topic/$6446tw/interactions) ---  [Engagements 24-Hour Chart Data](/topic/$6446tw/time-series/interactions.tsv) **Current Value**: XX **Daily Average**: XX **1 Week**: XXX +24% **1 Month**: XXXXX -XX% **6 Months**: XXXXXX +58% **1 Year**: XXXXXX +87% **1-Year High**: XXX on 2024-12-08 **1-Year Low**: X on 2024-12-22 | Social Network | X | YouTube | | -------------- | - | ------- | | Engagements | XX | X | ### Mentions: X [#](/topic/$6446tw/posts_active) ---  [Mentions 24-Hour Chart Data](/topic/$6446tw/time-series/posts_active.tsv) **Current Value**: X **Daily Average**: X **1 Week**: XX +12% **1 Month**: XX -XXXX% **6 Months**: XXX +110% **1 Year**: XXX +279% **1-Year High**: XX on 2025-05-08 **1-Year Low**: X on 2024-07-27 | Social Network | X | YouTube | | -------------- | - | ------- | | Mentions | XX | X | ### Creators: X [#](/topic/$6446tw/contributors_active) ---  [Creators 24-Hour Chart Data](/topic/$6446tw/time-series/contributors_active.tsv) X unique social accounts have posts mentioning PharmaEssentia Corporation in the last XX hours which is no change from in the previous XX hours **Daily Average**: X **1 Week**: X +14% **1 Month**: X -XX% **6 Months**: XX +50% **1 Year**: XX +167% **1-Year High**: X on 2025-06-10 **1-Year Low**: X on 2024-07-27 ### Sentiment: XX% [#](/topic/$6446tw/sentiment) ---  [Sentiment 24-Hour Chart Data](/topic/$6446tw/time-series/sentiment.tsv) **Current Value**: XX% **Daily Average**: XX% **1 Week**: XX% -XX% **1 Month**: XX% -XX% **6 Months**: XX% -XX% **1 Year**: XX% -XX% **1-Year High**: XXX% on 2024-12-01 **1-Year Low**: XX% on 2025-05-20 **Most Supportive Themes** - **Positive Developments:** (90%) Positive sentiment around patient events, partnerships, and Phase X data. - **Strategic Growth:** (9%) Company growth pillars and innovative therapies are being discussed. **Most Critical Themes** - **Regulatory Scrutiny:** (0.01%) Regulatory scrutiny indicated by a new FDA Form XXX. Network engagement breakdown: | Network | Positive | % | Neutral | % | Negative | % | | ------- | -------- | - | ------- | - | -------- | - | | X | XX | XX% | XX | XX% | X | X% | | YouTube | X | X% | X | XX% | X | X% | | | | | | | | | | Total | XX | XX% | XX | XX% | X | X% | ### Market Cap: $undefined [#](/topic/$6446tw/market_cap) ---  [Market Cap 24-Hour Chart Data](/topic/$6446tw/time-series/market_cap.tsv) **Current Value**: $undefined **Daily Average**: $XXXXXXXXXXXXXXX **1-Year High**: $XXXXXXXXXXXXXXX on 2025-02-17 **1-Year Low**: $XXXXXXXXXXXXXXX on 2025-03-31 **Top assets mentioned** In the posts about PharmaEssentia Corporation in the last XX hours [Merck & Co., Inc. (MRK)](/topic/$mrk) [Innovative Solutions & Support (ISSC)](/topic/$issc) [Novartis AG (NVS)](/topic/novartis) **Top topics mentioned** In the posts about PharmaEssentia Corporation in the last XX hours [vera](/topic/vera), [positions](/topic/positions), [stocks healthcare](/topic/stocks-healthcare), [supported](/topic/supported), [bose](/topic/bose), [if you](/topic/if-you), [taiwan](/topic/taiwan), [$mrk](/topic/$mrk), [pi](/topic/pi), [approved](/topic/approved), [$issc](/topic/$issc), [mesa](/topic/mesa), [novartis](/topic/novartis), [$novnsw](/topic/$novnsw), [superior](/topic/superior), [stocks](/topic/stocks) ### Top Social Posts [#](/topic/$6446tw/posts) --- Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "For Buzz advocating for his own health and finding a specialist he could partner with were critical steps following his polycythemia vera diagnosis. Hear Buzz tell the story of his PV journey. Listen to more PV patient stories:" [@PharmaEssentia](/creator/x/PharmaEssentia) on [X](/post/tweet/1948812787154636849) 2025-07-25 18:29:10 UTC XXX followers, XX engagements "During BIO AsiaTaiwan 2025 GeneOnline visited PharmaEssentia a global biopharmaceutical company known for developing innovative therapies for hematologic malignancies cancers and immune-related diseases. The company outlined its four strategic pillars for growth: 1) Ropeginterferon alfa-2b (BESREMi) a long-acting mono-pegylated interferon already approved for polycythemia vera in the U.S. EU and Asia 2) a growing immune-oncology pipeline featuring anti-TIM-3 and anti-PD-1 checkpoint inhibitors 3) its proprietary PEGylation platform for creating long-acting biologics Stay informed throughout" [@GeneOnlineNews](/creator/x/GeneOnlineNews) on [X](/post/tweet/1948338551248310716) 2025-07-24 11:04:43 UTC 4754 followers, XX engagements "Looking for a new role Join our team at PharmaEssentia where science and purpose come together to drive patient impact. Were hiring across multiple departments including Commercial R&D Medical BD and more. Explore open positions:" [@PharmaEssentia](/creator/x/PharmaEssentia) on [X](/post/tweet/1947650413999587666) 2025-07-22 13:30:18 UTC XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
PharmaEssentia is hiring across multiple departments, with positive sentiment around patient events and partnerships. New FDA Form XXX posted, indicating potential regulatory scrutiny.
PharmaEssentia Corporation is a biopharmaceutical company.
Price 24-Hour Chart Data
The price appears stable, likely due to positive Phase X data and anticipation for EHA 2025 presentations, despite the recent FDA Form XXX.
1-Year High: $XXX on 2025-02-17
1-Year Low: $XXXXXX on 2025-04-09
AltRank 24-Hour Chart Data
PharmaEssentia Corporation is currently AltRank #undefined based on combined combined social and market metrics
Daily Average: XXXXX
1-Year High: XXXXX on 2025-01-21
1-Year Low: XX on 2025-03-13
Galaxy Score 24-Hour Chart Data
Current Value: XX
Daily Average: XX
1-Year High: XX on 2025-06-25
1-Year Low: XX on 2025-02-08
Engagements 24-Hour Chart Data
Current Value: XX
Daily Average: XX
1 Week: XXX +24%
1 Month: XXXXX -XX%
6 Months: XXXXXX +58%
1 Year: XXXXXX +87%
1-Year High: XXX on 2024-12-08
1-Year Low: X on 2024-12-22
Social Network | X | YouTube |
---|---|---|
Engagements | XX | X |
Mentions 24-Hour Chart Data
Current Value: X
Daily Average: X
1 Week: XX +12%
1 Month: XX -XXXX%
6 Months: XXX +110%
1 Year: XXX +279%
1-Year High: XX on 2025-05-08
1-Year Low: X on 2024-07-27
Social Network | X | YouTube |
---|---|---|
Mentions | XX | X |
Creators 24-Hour Chart Data
X unique social accounts have posts mentioning PharmaEssentia Corporation in the last XX hours which is no change from in the previous XX hours
Daily Average: X
1 Week: X +14%
1 Month: X -XX%
6 Months: XX +50%
1 Year: XX +167%
1-Year High: X on 2025-06-10
1-Year Low: X on 2024-07-27
Sentiment 24-Hour Chart Data
Current Value: XX%
Daily Average: XX%
1 Week: XX% -XX%
1 Month: XX% -XX%
6 Months: XX% -XX%
1 Year: XX% -XX%
1-Year High: XXX% on 2024-12-01
1-Year Low: XX% on 2025-05-20
Most Supportive Themes
Most Critical Themes
Network engagement breakdown:
Network | Positive | % | Neutral | % | Negative | % |
---|---|---|---|---|---|---|
X | XX | XX% | XX | XX% | X | X% |
YouTube | X | X% | X | XX% | X | X% |
Total | XX | XX% | XX | XX% | X | X% |
Market Cap 24-Hour Chart Data
Current Value: $undefined
Daily Average: $XXXXXXXXXXXXXXX
1-Year High: $XXXXXXXXXXXXXXX on 2025-02-17
1-Year Low: $XXXXXXXXXXXXXXX on 2025-03-31
Top assets mentioned In the posts about PharmaEssentia Corporation in the last XX hours
Merck & Co., Inc. (MRK) Innovative Solutions & Support (ISSC) Novartis AG (NVS)
Top topics mentioned In the posts about PharmaEssentia Corporation in the last XX hours
vera, positions, stocks healthcare, supported, bose, if you, taiwan, $mrk, pi, approved, $issc, mesa, novartis, $novnsw, superior, stocks
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"For Buzz advocating for his own health and finding a specialist he could partner with were critical steps following his polycythemia vera diagnosis. Hear Buzz tell the story of his PV journey. Listen to more PV patient stories:"
@PharmaEssentia on X 2025-07-25 18:29:10 UTC XXX followers, XX engagements
"During BIO AsiaTaiwan 2025 GeneOnline visited PharmaEssentia a global biopharmaceutical company known for developing innovative therapies for hematologic malignancies cancers and immune-related diseases. The company outlined its four strategic pillars for growth: 1) Ropeginterferon alfa-2b (BESREMi) a long-acting mono-pegylated interferon already approved for polycythemia vera in the U.S. EU and Asia 2) a growing immune-oncology pipeline featuring anti-TIM-3 and anti-PD-1 checkpoint inhibitors 3) its proprietary PEGylation platform for creating long-acting biologics Stay informed throughout"
@GeneOnlineNews on X 2025-07-24 11:04:43 UTC 4754 followers, XX engagements
"Looking for a new role Join our team at PharmaEssentia where science and purpose come together to drive patient impact. Were hiring across multiple departments including Commercial R&D Medical BD and more. Explore open positions:"
@PharmaEssentia on X 2025-07-22 13:30:18 UTC XXX followers, XX engagements
/topic/$6446tw